GLP-1 Coverage Changes and the Rising Cost of Weight Loss Medications
The increasing popularity of GLP-1 receptor agonists for weight loss is creating a new challenge for health insurance plans and individuals alike. Driven by demand and high costs, coverage for these medications is evolving, impacting access for many. This article examines the recent changes in GLP-1 coverage, the reasons behind them, and what it means for those currently using or considering these drugs.
What are GLP-1s?
GLP-1 receptor agonists are a class of drugs originally developed to treat type 2 diabetes. They perform by mimicking the effects of the naturally occurring GLP-1 hormone, which helps regulate blood sugar, slows digestion, and can promote weight loss. Drugs in this class include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Cleveland Clinic explains that these medications reduce appetite, increase feelings of fullness, and can alter how the body absorbs fat or burns calories.
Colorado State Employee Medical Benefits Changes
As of July 1, 2025, the State of Colorado will remove coverage for GLP-1s specifically for weight loss under its employee medical plans offered through Cigna and Kaiser Permanente. Colorado Department of Human Resources announced this change due to the high cost of these medications. Although, employees actively taking GLP-1s for weight loss as of June 30, 2025, will be “grandfathered” into continued coverage, but with an increased co-pay – rising from $30 to $120 beginning July 1, 2025.
Why the Coverage Changes?
The primary driver behind the shift in coverage is the cost of GLP-1 medications. The State of Colorado cited the sustainability and affordability of its benefits program as key considerations in making this difficult decision. DHR Colorado explicitly states that the high cost of GLP-1 drugs for obesity conditions prompted the removal of coverage.
Alternative Weight Management Support
Despite the changes in GLP-1 coverage, the State of Colorado remains committed to supporting employee health. The State will continue to support employees’ efforts to achieve a healthy weight through its award-winning STATE OF HEALTH program, as well as various programs and covered services offered by Cigna and Kaiser Permanente. These evidence-based programs have a proven track record of success.
Economic Considerations of Obesity Medications
A systematic review published in September 2025 highlighted the economic evaluation of medications used in the prevention and treatment of obesity. The study noted that Orlistat and naltrexone-bupropion have been recognized as cost-effective choices for health systems in some studies.
Potential Risks and Considerations
The Mayo Clinic emphasizes that weight loss medications are not a quick fix and arrive with potential risks and side effects. It’s crucial for individuals to discuss these with their healthcare provider to determine if these medications are appropriate for their specific health needs. The FDA similarly has concerns regarding weight-loss drugs obtained from compounding pharmacies as of January 21, 2026.
Looking Ahead
The evolving landscape of GLP-1 coverage underscores the need for ongoing discussions about the affordability and accessibility of weight loss medications. As more research emerges and alternative treatment options are explored, it’s likely that coverage policies will continue to adapt. Individuals seeking weight loss support should consult with their healthcare provider to explore the most appropriate and cost-effective strategies for their individual circumstances.